Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
linear decrease » linear increase (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
linear decrease » linear increase (Expand Search)
-
1701
-
1702
-
1703
-
1704
-
1705
-
1706
-
1707
-
1708
-
1709
-
1710
Trends analysis in diabetes mellitus diagnosis according to relative handgrip strength.
Published 2024Subjects: -
1711
-
1712
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1713
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1714
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
1715
-
1716
-
1717
-
1718
-
1719
-
1720